Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pru p 3 sublingual immunotherapy
- Development stage
- Unknown
- Lead developer
- Fundación IMABIS
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Pru p 3 sublingual immunotherapy (SLIT-Peach) is an allergen-specific immunotherapy designed to treat lipid transfer protein (LTP) allergy, particularly in patients with severe reactions to peach and other LTP-containing foods. The active ingredient is a peach extract enriched with Pru p 3, the primary nonspecific lipid transfer protein (nsLTP) from *Prunus persica*. The therapy works by inducing immunological tolerance, characterized by the suppression of allergen-specific effector T cells, the upregulation of regulatory T (Treg) cells, and the modulation of monocyte-derived dendritic cell (moDC) activity. Developed by the Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) and Carlos Haya Hospital, and manufactured by ALK-Abelló, the drug has undergone Phase 3 clinical evaluation in Spain.
- Brand names
- SLIT-Peach
- Other names
- SLIT-peachsublingual immunotherapy with Pru p 3peach nsLTP immunotherapy
02
Targets
TCR (T cell antigen receptor complex)Pru p 3-specific Immunoglobulin EBCR (Immunoglobulin G B Cell Receptor)Peanut-specific IgE (Peanut-specific immunoglobulin E)
Beyond the preview
Go deeper on Pru p 3 sublingual immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pru p 3 sublingual immunotherapy.